Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 3Anemia 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Fatigue 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Critical Illness 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 7Nivolumab 4Carboplatin 4Taxes 3Paclitaxel 3Gene Expression Profiling 3rucaparib 2aflibercept 2Radiotherapy 2Polymerase Chain Reaction 2Leucovorin 2Irinotecan 2Interleukin-12 Subunit p35 2Fluorouracil 2Drug Therapy 2Capecitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2veliparib 1trastuzumab deruxtecan 1tocilizumab 1selinexor 1olaparib 1liposomal doxorubicin 1eribulin 1entinostat 1dehydroftorafur 1cc-486 1cabozantinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Darbepoetin alfa × Genitourinary × Clear all
NCT06184867 2026-03-06

CATALYST

Rutgers, The State University of New Jersey

Phase NA Completed
50 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡